Debiec-Rychter M - Search Results

1

A sarcoma at the site of previous extravasation of adriamycin.

Ceulemans J, De Wever I, Sciot R, Debiec-Rychter M, van Oosterom AT. Ceulemans J, et al. Sarcoma. 2002;6(4):135-9. doi: 10.1080/1357714021000066386. Sarcoma. 2002. PMID: 18521350 Free PMC article.

2

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.

Van Looy T, Gebreyohannes YK, Wozniak A, Cornillie J, Wellens J, Li H, Vanleeuw U, Floris G, Debiec-Rychter M, Sciot R, Schöffski P. Van Looy T, et al. Clin Sarcoma Res. 2014 Aug 10;4:10. doi: 10.1186/2045-3329-4-10. eCollection 2014. Clin Sarcoma Res. 2014. PMID: 25132955 Free PMC article.

3

Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation.

Floris G, Debiec-Rychter M, Wozniak A, Magrini E, Manfioletti G, De Wever I, Tallini G, Sciot R. Floris G, et al. Diagn Mol Pathol. 2007 Dec;16(4):243-8. doi: 10.1097/PDM.0b013e3180645105. Diagn Mol Pathol. 2007. PMID: 18043289

4

Lipoblastoma in a 23-year-old male: distinction from atypical lipomatous tumor using cytogenetic and fluorescence in-situ hybridization analysis.

Sciot R, De Wever I, Debiec-Rychter M. Sciot R, et al. Virchows Arch. 2003 May;442(5):468-71. doi: 10.1007/s00428-003-0799-x. Epub 2003 Apr 5. Virchows Arch. 2003. PMID: 12684772

5

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, Sciot R. Debiec-Rychter M, et al. J Pathol. 2004 Apr;202(4):430-8. doi: 10.1002/path.1546. J Pathol. 2004. PMID: 15095270

6

Gastrointestinal stromal tumor of the prostate.

Van der Aa F, Sciot R, Blyweert W, Ost D, Van Poppel H, Van Oosterom A, Debiec-Rychter M, De Ridder D. Van der Aa F, et al. Urology. 2005 Feb;65(2):388. doi: 10.1016/j.urology.2004.08.045. Urology. 2005. PMID: 15708062

7

Cutaneous aneurysmal fibrous histiocytoma with a t(12;19)(p12;q13) as the sole cytogenetic anomaly.

Botrus G, Sciot R, Debiec-Rychter M. Botrus G, et al. Cancer Genet Cytogenet. 2006 Jan 15;164(2):155-8. doi: 10.1016/j.cancergencyto.2005.08.020. Cancer Genet Cytogenet. 2006. PMID: 16434321

8

GIST under imatinib therapy.

Sciot R, Debiec-Rychter M. Sciot R, et al. Semin Diagn Pathol. 2006 May;23(2):84-90. doi: 10.1053/j.semdp.2006.08.005. Semin Diagn Pathol. 2006. PMID: 17193821 Review.

9

Is 4q13 a recurring breakpoint in solitary fibrous tumors?

Debiec-Rychter M, de Wever I, Hagemeijer A, Sciot R. Debiec-Rychter M, et al. Cancer Genet Cytogenet. 2001 Nov;131(1):69-73. doi: 10.1016/s0165-4608(01)00489-7. Cancer Genet Cytogenet. 2001. PMID: 11734322

10

Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.

Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Pauwels P, et al. Histopathology. 2005 Jul;47(1):41-7. doi: 10.1111/j.1365-2559.2005.02179.x. Histopathology. 2005. PMID: 15982322

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

323 results

Search Page

Filters